Evaxion Biotech announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies EVX-01 and EVX-02 in the second quarter of 2023. By mid-2023, Evaxion will present the full clinical readout of EVX-01 in metastatic melanoma and of EVX-02 in patients with resected malignant melanoma. Both compounds are neoantigen-targeting immunotherapies. Evaxion has previously presented interim data for both programs: EVX-01 Phase 1 interim data from 9 patients as previously communicated here: High response rate to the combination treatment, compared to historical data from studies where patients received anti-PD1 treatment alone. The full readout will include results from 13 patients with metastatic melanoma. EVX-02 Phase I/2a interim data from 8 patients as previously communicated here: Robust and long-lasting CD4+ and CD8+ specific T-cell responses in all patients, providing proof of mechanism for the DNA-delivery technology. The full readout will include both immune monitoring data and clinical outcome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVAX:
- Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
- Evaxion Biotech signs vaccine discovery collaboration agreement with ExpreS2ion
- Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate
- Evaxion Announces Third Quarter 2022 Financial Results and Business Update
- Evaxion Biotech intends to further increase focus on EVX-01, EVX-02/03 assets